Drug intelligence / Profile preview

MLC501

Development stage: Unknown
Lead developer: Moleac

Overview

MLC501 is a botanical drug candidate being developed by Moleac for the treatment of post-stroke recovery and post-traumatic brain injury (TBI) recovery. Currently in Phase 2 clinical development, MLC501 is a complex botanical formulation designed to enhance the brain's natural repair mechanisms, such as neurogenesis and synaptogenesis, following acute neurological injury. While the specific molecular targets and composition are not publicly detailed, the drug is part of Moleac's broader portfolio of neurorestorative therapies, which includes the marketed NeuroAiD products (MLC601/MLC901). MLC501 is positioned as a therapeutic intervention to improve functional outcomes and long-term recovery in patients who have experienced cerebrovascular accidents or head trauma.

Beyond the preview

Go deeper on MLC501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLC501.

Explore the full profile